2seventy bio (TSVT) to Release Earnings on Wednesday

2seventy bio (NASDAQ:TSVT) will issue its quarterly earnings data before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

2seventy bio (NASDAQ:TSVT) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). The company had revenue of $12.44 million for the quarter, compared to analyst estimates of $11.93 million. 2seventy bio had a negative return on equity of 67.59% and a negative net margin of 313.51%. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Stock Down 1.7 %

Shares of NASDAQ:TSVT traded down $0.07 during trading on Tuesday, hitting $3.98. 267,818 shares of the company were exchanged, compared to its average volume of 975,093. 2seventy bio has a 1-year low of $1.53 and a 1-year high of $6.79. The business’s 50 day moving average is $4.21 and its 200-day moving average is $4.63. The company has a market capitalization of $204.59 million, a P/E ratio of -0.90 and a beta of 1.77.

Analyst Ratings Changes

Several research firms have recently issued reports on TSVT. Morgan Stanley lowered their price objective on 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Canaccord Genuity Group raised 2seventy bio to a “strong-buy” rating in a report on Thursday, May 9th. Wedbush restated a “neutral” rating and set a $5.00 price objective on shares of 2seventy bio in a research report on Thursday, June 27th. Citigroup boosted their target price on shares of 2seventy bio from $9.00 to $12.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, The Goldman Sachs Group downgraded shares of 2seventy bio from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $5.00 to $2.00 in a report on Thursday, June 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $11.43.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.